Phase 1 Sickle cell disease trials recruiting now

All Sickle cell disease trials, every phase

Other phases for Sickle cell disease

Phase 1 Sickle cell disease trials

• 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
  NCT07015684 · Phase: Phase 1 · Ages: 12 Years to 50 Years · Sex: All (male and female) · 1 location
• A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
  NCT07187973 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
  NCT06546670 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 55 Years · Sex: All (male and female) · 10 locations
• A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
  NCT04055818 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  NCT06481306 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
  NCT05685368 · Phase: Phase 1, Phase 2 · Ages: 14 Years to 21 Years · Sex: All (male and female) · 1 location
• Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
  NCT02447874 · Phase: Phase 1, Phase 2 · Ages: 7 Years to 21 Years · Sex: All (male and female) · 2 locations
• Cannabidiol in Sickle Cell Disease
  NCT06930703 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
  NCT07432867 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 35 Years · Sex: All (male and female) · 1 location
• Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
  NCT07566494 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
  NCT04819841 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 50 Years · Sex: All (male and female) · 6 locations
• Gene Editing For Sickle Cell Disease
  NCT06506461 · Phase: Phase 1 · Ages: 18 Years to 24 Years · Sex: All (male and female) · 1 location
• Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
  NCT03279094 · Phase: Phase 1 · Ages: 1 Year to 30 Years · Sex: All (male and female) · 1 location
• Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
  NCT06647979 · Phase: Phase 1 · Ages: 13 Years to 40 Years · Sex: All (male and female) · 1 location
• Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
  NCT06399107 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 90 Years · Sex: All (male and female) · 1 location
• Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
  NCT07226219 · Phase: Phase 1 · Ages: 8 Years to 17 Years · Sex: All (male and female) · 1 location
• Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
  NCT07708714 · Phase: Phase 1, Phase 2 · Ages: 11 Years to 18 Years · Sex: All (male and female) · 1 location
• Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
  NCT07599176 · Phase: Phase 1, Phase 2 · Ages: 4 Years to 65 Years · Sex: All (male and female) · 1 location
• RH Genotype Matched RBC Transfusions
  NCT04156893 · Phase: Phase 1, Phase 2 · Ages: 6 Months and older · Sex: All (male and female) · 1 location
• Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
  NCT03128996 · Phase: Phase 1, Phase 2 · Ages: 1 Day to 21 Years · Sex: All (male and female) · 4 locations
• Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
  NCT04008368 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 80 Years · Sex: All (male and female) · 1 location
• Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
  NCT07252050 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 45 Years · Sex: All (male and female) · 4 locations
• SCD Stem Cell Mobilization and Apheresis Using Motixafortide
  NCT06442761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
  NCT01245179 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
  NCT05904093 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
  NCT03653338 · Phase: Phase 1, Phase 2 · Ages: 5 Years to 40 Years · Sex: All (male and female) · 1 location
• Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
  NCT04774536 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 35 Years · Sex: All (male and female) · 2 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.